{"id":249662,"date":"2026-09-16T15:10:22","date_gmt":"2026-09-16T09:40:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=249662"},"modified":"2026-09-16T15:10:22","modified_gmt":"2026-09-16T09:40:22","slug":"entero-healthcare-solutions-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Entero Healthcare Solutions Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Entero Healthcare Solutions share price Rs 1,741.60 on 16 September 2026, down 3.36%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 52.00 crore. Q2 FY26 base a profit of Rs 37.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Entero Healthcare Solutions Q2 results date for FY27 is not confirmed, and Entero Healthcare Solutions Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 1,571.00 crore in revenue and a profit of Rs 37.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Entero Healthcare Solutions Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/entero\/entero-healthcare-solutions-ltd-share-price-today\">Entero Healthcare Solutions Ltd.<\/a>, Entero Healthcare Solutions is a pharmaceutical and healthcare products distribution company that supplies medicines, surgical and other healthcare products to hospitals, pharmacies and retailers across India.. The stock traded at Rs 1,741.60 on the NSE on 16 September 2026, down 3.36% from the previous close of Rs 1,802.10, about 9.3% below its 52-week high of Rs 1,920.00 and 84.5% above its 52-week low of Rs 944.00.<\/p>\n<p>What makes the Entero Healthcare Solutions Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,571.00 crore of revenue and a profit of Rs 37.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 1,940.00 crore and a profit of Rs 52.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=entero_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#When_Is_the_Entero_Healthcare_Solutions_Q2_Results_FY27_Date\" title=\"When Is the Entero Healthcare Solutions Q2 Results FY27 Date?\">When Is the Entero Healthcare Solutions Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Entero_Healthcare_Solutions_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Entero Healthcare Solutions Q2 Results Expectations: What the Market Is Actually Tracking\">Entero Healthcare Solutions Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Entero_Healthcare_Solutions_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Entero Healthcare Solutions Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Entero Healthcare Solutions Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Entero_Healthcare_Solutions_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Entero Healthcare Solutions Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Entero Healthcare Solutions Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Entero_Healthcare_Solutions_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Entero Healthcare Solutions Quarterly Results Trend Over the Last Four Quarters\">Entero Healthcare Solutions Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Entero_Healthcare_Solutions_Q2_Results_FY27\" title=\"Key Factors That Could Shape Entero Healthcare Solutions Q2 Results FY27\">Key Factors That Could Shape Entero Healthcare Solutions Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Valuation_Snapshot\" title=\"Valuation Snapshot\">Valuation Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Technical_and_Price_Context\" title=\"Technical and Price Context\">Technical and Price Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Balance_Sheet_and_Payout\" title=\"Balance Sheet and Payout\">Balance Sheet and Payout<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Entero_Healthcare_Solutions_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Entero Healthcare Solutions Q2 Results FY27: Share Price and Valuation Going Into the Print\">Entero Healthcare Solutions Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Entero_Healthcare_Solutions_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Entero Healthcare Solutions Q2 Results Are Announced\">What Investors Should Watch When Entero Healthcare Solutions Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Entero_Healthcare_Solutions_Q2_Results_FY27\" title=\"Conclusion on Entero Healthcare Solutions Q2 Results FY27\">Conclusion on Entero Healthcare Solutions Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#FAQs_on_Entero_Healthcare_Solutions_Q2_Results_FY27\" title=\"FAQs on Entero Healthcare Solutions Q2 Results FY27\">FAQs on Entero Healthcare Solutions Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_is_the_Entero_Healthcare_Solutions_Q2_results_date_for_FY27\" title=\"What is the Entero Healthcare Solutions Q2 results date for FY27?\">What is the Entero Healthcare Solutions Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Entero_Healthcare_Solutions_Q2_results_2026_cover\" title=\"What quarter do the Entero Healthcare Solutions Q2 results 2026 cover?\">What quarter do the Entero Healthcare Solutions Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_were_the_Entero_Healthcare_Solutions_Q1_FY27_results\" title=\"What were the Entero Healthcare Solutions Q1 FY27 results?\">What were the Entero Healthcare Solutions Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_were_Entero_Healthcare_Solutions_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Entero Healthcare Solutions Q2 FY26 results in the September 2025 quarter?\">What were Entero Healthcare Solutions Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Entero_Healthcare_Solutions_Q2_results_expectations_this_quarter\" title=\"What are the main Entero Healthcare Solutions Q2 results expectations this quarter?\">What are the main Entero Healthcare Solutions Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#What_is_Entero_Healthcare_Solutions_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Entero Healthcare Solutions share price today ahead of the Q2 earnings?\">What is Entero Healthcare Solutions share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations\/#Is_Entero_Healthcare_Solutions_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Entero Healthcare Solutions a good stock to buy before the Q2 results?\">Is Entero Healthcare Solutions a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Entero_Healthcare_Solutions_Q2_Results_FY27_Date\"><\/span><strong>When Is the Entero Healthcare Solutions Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Entero Healthcare Solutions Q2 results date for FY27 is not confirmed. As of 16 September 2026, Entero Healthcare Solutions Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Entero Healthcare Solutions Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/india-glycols-q2-results-fy27-preview-date-expectations\">India Glycols Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>The Entero Healthcare Solutions Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Entero Healthcare Solutions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Entero_Healthcare_Solutions_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Entero Healthcare Solutions Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Entero Healthcare Solutions Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Entero Healthcare Solutions. The Entero Healthcare Solutions Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>Entero Healthcare Solutions Q2 results for the September 2026 quarter will be watched against a backdrop of steady revenue growth over the last five reported quarters. Revenue rose from Rs1,404 crore in the June 2025 quarter to Rs1,571 crore in September 2025, Rs1,707 crore in December 2025, Rs1,910 crore in March 2026 and Rs1,940 crore in the June 2026 quarter, a consistent upward trend without any sequential decline. This steady climb sets the context in which Entero Healthcare Solutions Q2 results will be assessed, since the company has not reported a single revenue contraction across these five quarters. As the distribution business scales its network of hospitals, pharmacies and retailers, investors tracking Entero Healthcare Solutions Q2 results for the September 2026 quarter will look for whether the same gradual, sequential growth pattern seen in prior quarters continues, based purely on the historical trend rather than any forward guidance.<\/p>\n<p>Alongside revenue, Entero Healthcare Solutions Q2 results have historically tracked a gradual improvement in operating margin. Operating profit margin moved from 3.6% in June 2025 to 4.0% in both September and December 2025, then to 4.5% in March 2026 and 5.0% in June 2026, a steady, uninterrupted uptrend. Net profit followed a broadly similar path, rising from Rs30 crore in June 2025 to Rs37 crore in September 2025, easing slightly to Rs34 crore in December 2025, then climbing to Rs45 crore in March 2026 and Rs52 crore in June 2026. None of these five quarters were loss-making. The margin expansion, even if modest in absolute percentage terms, reflects the operating efficiency gains of a capital-light distribution model as scale increases. This combination of rising revenue, expanding margin and rising profit across five straight quarters is the core historical pattern behind Entero Healthcare Solutions Q2 results heading into the new reporting period.<\/p>\n<p>On valuation, Entero Healthcare Solutions Q2 results arrive with the stock trading at a trailing P\/E of 58.3x against a book value of Rs388, a combination that reflects both its post-IPO scarcity and the market&#8217;s assumption of continued margin gains rather than current profitability alone. Return on equity stands at a modest 6.94%, notably below return on capital employed of 10.5%, a gap the screener data flags as typical of a still-maturing, capital-light distribution business. The company pays no dividend, with a yield of 0.00%. The biggest data-quality point to flag ahead of Entero Healthcare Solutions Q2 results for the September 2026 quarter is this ROE-ROCE gap and the high trailing multiple. None of the historical revenue or profit trend discussed above should be read as a projection for the September 2026 quarter itself, only as context in which Entero Healthcare Solutions Q2 results will eventually be compared.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Entero Healthcare Solutions Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Entero_Healthcare_Solutions_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Entero Healthcare Solutions Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Entero Healthcare Solutions Ltd. reported revenue of Rs 1,940.00 crore in Q1 FY27, up 38.18% from Rs 1,404.00 crore in Q1 FY26, and a profit of Rs 52.00 crore at the net level, up 73.33% from Rs 30.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/indiamart-intermesh-q2-results-fy27-preview-date-expectations\">Indiamart Intermesh Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>Sequentially, revenue was up 1.57% over the March 2026 quarter figure of Rs 1,910.00 crore, and net profit was up 15.56% from Rs 45.00 crore in Q4 FY26. Operating margin stood at 3.6% in Q1 FY27 against 4.0% in the September 2025 quarter, which is the comparison the Entero Healthcare Solutions Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Entero_Healthcare_Solutions_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Entero Healthcare Solutions Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Entero Healthcare Solutions Ltd. reported revenue of Rs 1,571.00 crore and a profit of Rs 37.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Entero Healthcare Solutions Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 52.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 1,571.00 crore sits below the Rs 1,940.00 crore of the June 2026 quarter, which frames how much sequential movement the Entero Healthcare Solutions Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Entero_Healthcare_Solutions_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Entero Healthcare Solutions Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>1,571.00<\/td>\n<td>37.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>1,707.00<\/td>\n<td>34.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>1,910.00<\/td>\n<td>45.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>1,940.00<\/td>\n<td>52.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Entero Healthcare Solutions Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 1,571.00 crore to Rs 1,940.00 crore, and net profit from Rs 34.00 crore to Rs 52.00 crore. That spread is the honest context for the Entero Healthcare Solutions Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Entero_Healthcare_Solutions_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Entero Healthcare Solutions Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Entero Healthcare Solutions Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Entero Healthcare Solutions has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Snapshot\"><\/span><strong>Valuation Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Entero Healthcare Solutions trades at a trailing P\/E of 58.69x on an EPS of Rs29.67, against a book value of Rs388 per share, putting the price-to-book ratio at 4.49x. Return on equity is modest at 6.94%, a level that keeps the stock priced more on growth expectations than current profitability. The company does not pay a dividend, with a yield of 0.00%, so the return case rests entirely on price appreciation and future earnings growth rather than any income component. At a market capitalisation of around Rs7,577 crore, the valuation multiples sit well above what the current ROE alone would justify, reflecting the market&#8217;s assumption that margins and returns will keep improving.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Technical_and_Price_Context\"><\/span><strong>Technical and Price Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock&#8217;s 52-week range spans Rs944 on the low end to Rs1,920 on the high end, and the current market price of about Rs1,741.6 sits well above both its 50-day moving average of Rs1,449.06 and its 200-day moving average of Rs1,213.57. This places the stock in an established uptrend on a medium-term basis, with price trading at a meaningful premium to both averages. The RSI reading of 59.32 is in neutral to mildly positive territory, neither signalling an extreme overbought condition nor a weak, oversold setup. The recent close was down about 3.36% from the previous session&#8217;s price of Rs1,802.1.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Payout\"><\/span><strong>Balance Sheet and Payout<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Entero Healthcare Solutions carries a debt-to-equity ratio of 0.4, a moderate level of borrowings on the balance sheet that leaves room for further working-capital funding as the distribution business scales. The company does not currently pay a dividend, with the yield at 0.00%, so shareholder returns to date have depended entirely on the stock&#8217;s price performance rather than payouts. Combined with the book value of Rs388 per share and a price-to-book multiple of 4.49x, the balance sheet profile is that of a moderately funded distribution company still reinvesting rather than returning cash to shareholders.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Entero_Healthcare_Solutions_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Entero Healthcare Solutions Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Entero Healthcare Solutions share price today is Rs 1,741.60 on the NSE, down Rs 60.50 or 3.36% from the previous close of Rs 1,802.10 on 16 September 2026, ahead of the Entero Healthcare Solutions Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (16 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>ENTERO<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 1,741.60<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 1,920.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 944.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 7577 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>58.69<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>4.49<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 29.67<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 388.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.40<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>6.94%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 1449.06<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 1213.57<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>59.32<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 1449.06 and its 200-day average of Rs 1213.57, with a 14-day RSI of 59.32. None of this is a view on where the shares go once the Entero Healthcare Solutions Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Entero Healthcare Solutions Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Entero_Healthcare_Solutions_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Entero Healthcare Solutions Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Entero Healthcare Solutions Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 1,571.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 37.00 crore in that same quarter<\/li>\n<li>Operating margin against 3.6% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Entero Healthcare Solutions Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Entero_Healthcare_Solutions_Q2_Results_FY27\"><\/span><strong>Conclusion on Entero Healthcare Solutions Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Entero Healthcare Solutions Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Entero Healthcare Solutions Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Entero Healthcare Solutions Q2 results FY27 print faces a base of Rs 1,571.00 crore in revenue and a profit of Rs 37.00 crore, with the most recent quarter having delivered Rs 1,940.00 crore and a profit of Rs 52.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Entero Healthcare Solutions, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Entero_Healthcare_Solutions_Q2_Results_FY27\"><\/span><strong>FAQs on Entero Healthcare Solutions Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Entero_Healthcare_Solutions_Q2_results_date_for_FY27\"><\/span><strong>What is the Entero Healthcare Solutions Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Entero Healthcare Solutions Q2 results date for FY27 is not confirmed. Entero Healthcare Solutions Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Entero_Healthcare_Solutions_Q2_results_2026_cover\"><\/span><strong>What quarter do the Entero Healthcare Solutions Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Entero Healthcare Solutions Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Entero Healthcare Solutions Ltd. reports revenue, operating profit and net profit for that period, and the Entero Healthcare Solutions Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Entero_Healthcare_Solutions_Q1_FY27_results\"><\/span><strong>What were the Entero Healthcare Solutions Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Entero Healthcare Solutions Ltd. reported revenue of Rs 1,940.00 crore in Q1 FY27 and a profit of Rs 52.00 crore at the net level. Revenue was up 38.18% versus Q1 FY26 and net profit was up 73.33% from Rs 30.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Entero_Healthcare_Solutions_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Entero Healthcare Solutions Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Entero Healthcare Solutions Ltd. reported revenue of Rs 1,571.00 crore and a profit of Rs 37.00 crore in Q2 FY26. Operating margin was 4.0%. Those figures form the base for the Entero Healthcare Solutions Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Entero_Healthcare_Solutions_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Entero Healthcare Solutions Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Entero Healthcare Solutions Q2 results expectations centre on revenue against the Rs 1,571.00 crore base, net profit against a profit of Rs 37.00 crore, operating margin against 3.6% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Entero_Healthcare_Solutions_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Entero Healthcare Solutions share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Entero Healthcare Solutions share price is Rs 1,741.60 on the NSE as of 16 September 2026, down 3.36% from Rs 1,802.10. The stock is about 9.3% below its 52-week high of Rs 1,920.00 and 84.5% above its 52-week low of Rs 944.00, at a market capitalisation of Rs 7577 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Entero_Healthcare_Solutions_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Entero Healthcare Solutions a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Entero Healthcare Solutions Ltd. The stock trades at a price-to-book ratio of 4.49 with a return on equity of 6.94%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Entero Healthcare Solutions Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Entero Healthcare Solutions Q2 results date for FY27 is not confirmed. Entero Healthcare Solutions Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Entero Healthcare Solutions Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Entero Healthcare Solutions Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Entero Healthcare Solutions Ltd. reports revenue, operating profit and net profit for that period, and the Entero Healthcare Solutions Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Entero Healthcare Solutions Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Entero Healthcare Solutions Ltd. reported revenue of Rs 1,940.00 crore in Q1 FY27 and a profit of Rs 52.00 crore at the net level. Revenue was up 38.18% versus Q1 FY26 and net profit was up 73.33% from Rs 30.00 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Entero Healthcare Solutions Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Entero Healthcare Solutions Ltd. reported revenue of Rs 1,571.00 crore and a profit of Rs 37.00 crore in Q2 FY26. Operating margin was 4.0%. Those figures form the base for the Entero Healthcare Solutions Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Entero Healthcare Solutions Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Entero Healthcare Solutions Q2 results expectations centre on revenue against the Rs 1,571.00 crore base, net profit against a profit of Rs 37.00 crore, operating margin against 3.6% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Entero Healthcare Solutions share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Entero Healthcare Solutions share price is Rs 1,741.60 on the NSE as of 16 September 2026, down 3.36% from Rs 1,802.10. The stock is about 9.3% below its 52-week high of Rs 1,920.00 and 84.5% above its 52-week low of Rs 944.00, at a market capitalisation of Rs 7577 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Entero Healthcare Solutions a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Entero Healthcare Solutions Ltd. The stock trades at a price-to-book ratio of 4.49 with a return on equity of 6.94%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Entero Healthcare Solutions Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Entero Healthcare Solutions Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":249661,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-249662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["249661"],"rank_math_title":["Entero Healthcare Q2 FY27 Preview and Trends"],"rank_math_description":["Entero Healthcare Solutions Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Entero Healthcare Solutions Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/entero-healthcare-solutions-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/249662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=249662"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/249662\/revisions"}],"predecessor-version":[{"id":249663,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/249662\/revisions\/249663"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/249661"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=249662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=249662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=249662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}